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We sought to assess whether the effects of mesenchymal stromal cells (MSC) on lung inflammation and remodeling in
experimental emphysema would differ according to MSC source and administration route. Emphysema was induced in
C57BL/6 mice by intratracheal (IT) administration of porcine pancreatic elastase (0.1 UI) weekly for 1 month. After
the last elastase instillation, saline or MSCs (1×105), isolated from either mouse bone marrow (BM), adipose tissue
(AD) or lung tissue (L), were administered intravenously (IV) or IT. After 1 week, mice were euthanized. Regardless
of administration route, MSCs from each source yielded: 1) decreased mean linear intercept, neutrophil infiltration, and
cell apoptosis; 2) increased elastic fiber content; 3) reduced alveolar epithelial and endothelial cell damage; and 4)
decreased keratinocyte-derived chemokine (KC, a mouse analog of interleukin-8) and transforming growth factor-β
levels in lung tissue. In contrast with IV, IT MSC administration further reduced alveolar hyperinflation (BM-MSC) and
collagen fiber content (BM-MSC and L-MSC). Intravenous administration of BM- and AD-MSCs reduced the number of
M1 macrophages and pulmonary hypertension on echocardiography, while increasing vascular endothelial growth
factor. Only BM-MSCs (IV > IT) increased the number of M2 macrophages. In conclusion, different MSC sources and
administration routes variably reduced elastase-induced lung damage, but IV administration of BM-MSCs resulted in
better cardiovascular function and change of the macrophage phenotype from M1 to M2.
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Emphysema, a key feature of chronic obstructive pulmon-
ary disease (COPD), is characterized by the enlargement
of air spaces accompanied by destruction of parenchymal
structure and impaired pulmonary regeneration [1]. Cur-
rently, COPD is the fourth leading cause of death world-
wide, and so far there has been no effective therapy for
patients with emphysema [2]. One potential therapeutic
approach for emphysema has focused on inducing lung
repair and regeneration and/or decreasing chronic inflam-
mation by administering mesenchymal stem (stromal)* Correspondence: prmrocco@gmail.com
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unless otherwise stated.cells (MSCs) of bone marrow or adipose origin [3]. A
number of preclinical studies have shown that MSCs at-
tenuate lung inflammation and apoptosis in experimental
emphysema [4-7]. Furthermore, a recent clinical study
showed that the intravenous (IV) administration of non
HLA-matched allogeneic bone marrow MSCs in emphy-
sema patients is safe; however, no functional improvement
was reported, although a decrease in an inflammatory me-
diator, C-reactive protein, was observed in treated patients
[8]. Nevertheless, depending on the site of origin, MSCs
may have different phenotypes, including differences in
immunogenicity, anti-inflammatory and regenerative ac-
tivity, and expansibility in culture [9,10], which may lead
to differing results depending on MSC source. Therefore,
further comparative experimental studies are required to
better assess the efficacy of different sources of MSCs for
use in emphysema.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lection of the optimal administration route. While IV in-
jection of MSCs is generally utilized in preclinical studies
of experimental emphysema, due to ease of administration
and subsequent wide biodistribution [4,6,11,12], intratra-
cheal (IT) administration of MSCs also attenuates lung
damage [13,14]. Thus, no definite conclusion has been
reached regarding the optimal administration route of
MSCs in experimental emphysema.
The aims of the present study were to: (a) compara-
tively assess the extent to which different sources (bone
marrow, adipose, or lung tissue) of MSCs are able to de-
crease inflammation and promote alveolar epithelium
and endothelium repair, thereby improving lung function
in elastase-induced emphysema in mice, (b) investigate
whether IV versus IT administration of MSCs influences
their effectiveness on lung inflammation and remodeling,
and (c) evaluate the effects of IV versus IT delivery of the
aforementioned different sources of MSCs on elastase
(emphysema)-induced changes in cardiac function.
Materials and methods
This study was approved by the Ethics Committee of the
Health Sciences Centre, Federal University of Rio de
Janeiro. All animals received humane care in compliance
with the “Principles of Laboratory Animal Care” formu-
lated by the National Society for Medical Research and
the U.S. National Research Council “Guide for the Care
and Use of Laboratory Animals”.
Isolation and culture of bone marrow-, adipose tissue-,
and lung tissue-derived MSCs
Ten male C57BL/6 mice (weight 20–25 g, age
2 months) were used as donors. Bone marrow cells
were obtained from femurs and tibias. After isolation,
1 × 107 bone marrow-derived cells were cultured (37°C,
5% CO2) in T25 culture flasks (TPP, Schaffhausen,
Switzerland) with Dulbecco’s Modified Eagle Medium
(DMEM; Invitrogen, CA, USA) containing 15 mM
HEPES (Sigma, MO, USA), 15% inactivated fetal bovine
serum (FBS) (Invitrogen, CA, USA), 100 units/mL
penicillin, and 100 mg/mL streptomycin antibiotic so-
lution (Gibco, NM, USA). MSCs from lung and adipose
tissue (epididymal fat pad) were obtained as previously
described [15]. Tissues were collected, rinsed in PBS,
transferred to a Petri dish, and cut into small pieces.
The dissected pieces (around 0.2-0.8 cm3) were washed
with PBS, cut into smaller fragments, and subsequently
digested with collagenase type I (1 mg/mL in DMEM/
10 mM HEPES) for 30 minutes to 1 hour at 37°C.
Whenever gross remnants persisted after collagenase
digestion were allowed to settle for 1 to 3 minutes, and
the supernatant was transferred to a new tube contain-
ing fresh medium and centrifuged at 400 g for10 minutes at room temperature (RT). The pellets were re-
suspended in 3.5 mL D-MEM containing 1% antibiotic-
antimycotic solution DMEM (Invitrogen, CA, USA), seeded
in six-well dishes (3.5 mL/well), and incubated at 37°C in a
humidified atmosphere containing 5% CO2. On day 3 of
culture, the medium was changed and non-adherent cells
were removed. Adherent cells reaching 80% confluence
were passaged with 0.05% trypsin-EDTA solution (Gibco,
NM, USA) and then maintained in DMEM with 10% FBS
(complete medium).
At the third passage, approximately 1 × 106 cells were
characterized as MSCs according to the International
Society of Cellular Therapy Consensus, i.e., adherent
to plastic under standard conditions, expressing some
surface markers (CD73, CD90 and CD105) and lacking
expression of others (CD34, CD45, CD11b, CD19), and
demonstrating capacity to differentiate into mesenchymal
lineages under in vitro conditions [16]. Flow cytometry used
antibodies against CD45 (leukocytes), CD34 (hematopoietic
precursors), CD29 and CD45 (non-hematopoietic pre-
cursors), and Sca-1 (stem/progenitor cells) (BD Biosci-
ences, USA). The absence of CD34 and CD45 and the
presence of CD29, and Sca-1 were used to identify
MSCs [17]. To measure the small-angle forward scatter
(FSC) intensity (~0°–5°) and the limited-angle side scat-
ter (SSC) intensity (~85°–95°), a photodiode and a
photomultiplier tube were used respectively. The differ-
ent MSC populations were further characterized by
their capacity to differentiate into osteoblasts and chon-
droblasts. Osteogenic differentiation was induced by
culturing MSCs for up to 3 weeks in D-MEM 10% FBS
and 15 mM HEPES (Sigma, MO, USA), supplemented
with 10–8 M/l dexamethasone (Sigma, MO, USA),
5 μg/mL ascorbic acid 2-phosphate (Sigma, MO, USA),
and 10 mM/l β-glycerolphosphate (Sigma MO, USA). To
observe calcium deposition, cultures were stained with
Alizarin Red S (Nuclear, SP, Brazil). To induce chondro-
genic differentiation, MSCs were cultured in DMEM sup-
plemented with 10 ng/mL TGF-β1 (Sigma, MO, USA), 50
nM ascorbic acid 2-phosphate (Sigma, MO, USA), and
6.25 mg/mL insulin for 3 weeks. To confirm differenti-
ation, cells were fixed with 4% paraformaldehyde in PBS
for 1 hour at RT and stained with Alcian Blue pH 2.5.
Animal preparation and experimental protocol
C57BL/6 mice (weight: 20–25 g, age 2 months) were
randomly assigned to two main groups: control (C) and
emphysema (E). In group E, mice received IT pancreatic
porcine elastase (0.1 UI PPE in 50 μL saline) once a
week for 4 weeks [11], while group C received saline
(50 μL) using the same protocol. Three hours after the
last instillation, animals in the C and E groups were fur-
ther randomized to receive saline solution (0.9% NaCl,
50 μL, SAL), bone marrow MSCs (BM-MSC, 1 × 105 in
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saline), or lung MSCs (L-MSC, 1 × 105 in 50 μL saline)
by the IV or IT route (Figure 1). As we have previously
observed that administration of a control cell population
(lung fibroblasts) had no effect on the experimental end-
points in this model, this arm was not included in the
present study. Briefly, mice were anesthetized with sevo-
flurane and either the left jugular vein (for IV adminis-
tration) or the trachea (for IT administration) of each
mouse was exposed by ventral neck dissection and
MSCs slowly injected over a period of 2 min.
Echocardiography
For echocardiographic assessment of cardiac function,
three mice per experimental group were anesthetized
with isoflurane 1.5%, shaved over the precordial region,
and examined with a Vevo 770 apparatus (VisualSonics,
Toronto, ON, Canada) coupled to a 30 MHz transducer.
Images were obtained from the parasternal view. M-mode
images showed left ventricular muscle thickness. One long-
axis and four short-axis B-dimensional views of both ventri-
cles were acquired to calculate the left and right ventricular
areas [18]. Pulsed-wave Doppler was used to measure pul-
monary artery acceleration time (PAT), and pulmonary ar-
tery ejection time (PET) [19,20]. All parameters followed
American Society of Echocardiography and European Asso-
ciation of Cardiovascular Imaging recommendations.
Mechanical parameters
One week after therapy, the animals were sedated (diaze-
pam 1 mg i.p.), anesthetized (thiopental sodium 20 mg/
kg i.p.), tracheotomized, paralyzed (vecuronium bromide,Figure 1 Schematic flow chart (A) and timeline (B) of the study desig
instillation of 0.1 UI of pancreatic porcine elastase (PPE), SAL: injection of 50 μ
administration; AD-MSC: adipose tissue derived mesenchymal stromal cell (1 ×
(1 × 105) administration; IV/IT: intravenous or intratracheal injection 3 h after th
were analyzed at day 28.0.005 mg/kg i.v.), and ventilated with a constant flow ven-
tilator (Samay VR15; Universidad de la Republica,
Montevideo, Uruguay) set to the following parameters:
rate 100 breaths/min, tidal volume (VT) 0.2 mL, and frac-
tion of inspired oxygen (FiO2) 0.21. The anterior chest
wall was surgically removed and a positive end-expiratory
pressure of 2 cmH2O applied. Airflow and tracheal pres-
sure (Ptr) were measured. Lung mechanics were analyzed
by the end-inflation occlusion method. In an open chest
preparation, Ptr reflects transpulmonary pressure (PL).
Static lung elastance (Est, L) was determined by dividing
elastic recoil pressure (Pel) by VT. Lung mechanics pa-
rameters were measured 10 times in each animal. All data
were analyzed using ANADAT software (RHT-InfoData,
Inc., Montreal, Quebec, Canada). All experiments lasted
less than 15 min.
Lung histology
At the end of the experiment, laparotomy was per-
formed and heparin (1000 IU) injected into the vena
cava. The trachea was clamped at end-expiration, and
the abdominal aorta and vena cava were sectioned, pro-
ducing massive hemorrhage and terminal bleeding for
euthanasia. The right lung was then removed, fixed in
3% buffered formalin, and embedded in paraffin; 4-μm-
thick slices were cut and stained with hematoxylin–
eosin. Lung histology analysis was performed with an in-
tegrating eyepiece with a coherent system consisting of a
grid with 100 points and 50 lines of known length
coupled to a conventional light microscope (Olympus
BX51, Olympus Latin America-Inc., Brazil). The volume
fraction of hyperinflated, collapsed, and normal pulmonaryn. C: intratracheal instillation of 50 μL of saline, E: intratracheal
L of saline, BM-MSC: bone marrow mesenchymal stromal cell (1 × 105)
105) administration; L-MSC: lung derived mesenchymal stromal cell
e last instillation of saline or PPE; ♦: saline or PPE instillation; ★: all data
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of neutrophils in pulmonary tissue were determined by the
point-counting technique across 10–20 random, non-
coincident microscopic fields [21,22]. Collagen (Picrosirius
polarization method) and elastic fibers (Weigert’s resorcin
fuchsin method with oxidation) were computed around
the small airways and in the lung parenchyma, respectively,
using Image-Pro Plus 6.0 software [23].
Immunohistochemistry
Immunohistochemistry for macrophage subpopulations
(M1 and M2 phenotypes) in lung tissue was done using
iNOS rabbit anti-mouse polyclonal antibody (M1, cata-
log no. Rb-9242, Thermo Scientific) and arginase-1
rabbit anti-mouse polyclonal antibody (M2, catalog no.
sc-20150, Santa Cruz Biotechnology). Antibodies were
detected using a secondary antibody labeled with per-
oxidase (Histofine mouse MAX PO anti-rat and anti-
rabbit, Nichirei Biosciences, Tokyo, Japan) followed
by the chromogen substrate diaminobenzidine (Liquid
DAB, Dakocytomation, USA, catalog no. K3468). Analysis
was performed in 30 images of high-power fields (×400
magnification) per slide, taken with an Evolution VR
Cooled Color 13-bit digital camera (Media Cybernetics,
Canada) and manually selected under a light microscope
(Nikon Eclipse 400, Nikon Instruments Tokyo, Japan).
The areas occupied by nucleated macrophages and cells
with positive staining for the phenotype marker in each
tissue area were then calculated and expressed as frac-
tional area occupied by positive cells. The images were
analyzed using Image Pro Plus 4.5.1 software (Media
Cybernetics).
Enzyme-linked immunosorbent assay (ELISA)
Levels of keratinocyte-derived chemokine (KC, a mouse
analog of interleukin-8), transforming growth factor
(TGF)-β, and vascular endothelial growth factor (VEGF)
in lung tissue were evaluated by ELISA using matched
antibody pairs from PrepoTech and R & D Systems
(Minneapolis, MN, USA), according to manufacturer in-
structions. Results are expressed as pg/mL.
Transmission electron microscopy (TEM)
Three slices (2 × 2 × 2 mm) were cut from three different
segments of the left lung and fixed in glutaraldehyde
2.5% and phosphate buffer 0.1 M (pH = 7.4) for electron
microscopy (JEOL 1010 Transmission Electron Micro-
scope, Tokyo, Japan). On each lung electron microscopy
image (20 fields/animal), the following alterations were
analyzed: alveolar-capillary membrane damage, type II
pneumocyte lesion, and endothelial cell lesion [24]. Patho-
logic findings were graded on a five-point, semiquantita-
tive, severity-based scoring system as follows: 0 = normal
lung parenchyma, 1 = changes in 1–25%, 2 = changes in26–50%, 3 = changes in 51–75%, and 4 = changes in 76–
100% of examined tissue.
Apoptosis assay of lung
Terminal deoxynucleotidyl transferase biotin-dUTP
nick end labeling (TUNEL) staining was used to assay
cellular apoptosis [25]. Ten fields per section from re-
gions with cell apoptosis were examined at × 400 mag-
nification. A five-point, semiquantitative, severity-based
scoring system was used to assess the degree of apop-
tosis: 0 = normal lung parenchyma; 1 = 1–25%; 2 = 26–
50%; 3 = 51–75%; and 4 = 76–100% of examined tissue
[24]. The pathologist or technician working on the light
microscopy and TEM images was blinded to group
assignment.
Statistical analyses
One-way ANOVA followed by Tukey’s test was used to
compare the different parameters for each administra-
tion route. For non-parametric results, the Kruskal-
Wallis test followed by Dunn’s test was used. All tests
were performed using the Prism 5.0 software package
(GraphPad Software Inc., La Jolla, CA, USA), and statis-
tical significance was established as p < 0.05.
Results
Intravenous administration of lung-derived MSCs led to
immediate death of all mice, which may be associated
with the larger size of the L-MSCs (see below) or with
cellular clumping resulting in pulmonary embolism.
Thus, this group was not included in further analysis.
Conversely, survival rate in all other groups was 100%.
As no significant differences in any endpoint measures
were observed between any of the C groups (Table 1),
henceforth a single C group, which consists of the aver-
age of all C groups, was reported.
MSC characterization
All MSC sources were characterized as CD19−/CD34−/
CD45−/CD29+/Sca1+ by flow cytometry (Table 2). LD-
MSCs were 10% and 24% larger in size compared to
AD-MSCs and BM-MSCs, respectively. All MSC line-
ages were similarly capable of in vitro differentiation into
osteoblasts and chondroblasts.
Development of emphysema model induced by repeated
elastase doses
In the E-SAL group, the fractional area of alveolar col-
lapse, hyperinflation, and neutrophils in lung tissue
(Table 3, Figure 2), collagen fiber content around the
small airways (Figure 3), and lung cell apoptosis (Table 4)
were increased compared to C group, whereas the amount
of elastic fibers was reduced (Figure 4). Ultrastructural ana-
lysis of lung parenchyma in E-SAL animals demonstrated
Table 1 Characteristics of the control groups
Normal (%) Collapse (%) Hyperinflation (%) Lm (μm)
C
SAL
IV 93.23 ± 0.90 6.77 ± 0.90 0.00 ± 0.00 33.86 ± 2.93
IT 94.05 ± 1.98 5.95 ± 1.98 0.00 ± 0.00 33.80 ± 2.24
BM-MSC
IV
92.10 ± 2.46 7.90 ± 2.46 0.00 ± 0.00 36.43 ± 2.53
AD-MSC 94.53 ± 1.07 5.47 ± 1.07 0.00 ± 0.00 36.03 ± 2.28
BM-MSC
IT
91.58 ± 3.11 8.42 ± 3.11 0.00 ± 0.00 36.44 ± 0.32
AD-MSC 92.55 ± 1.01 7.45 ± 1.01 0.00 ± 0.00 35.96 ± 0.90
L-MSC 92.09 ± 2.97 7.91 ± 2.97 0.00 ± 0.00 36.77 ± 1.00
Values are means (±SD) of 7 animals in each group. All values were computed in ten random, non-coincident fields per mice. Fraction area of normal, collapsed,
and hyperinflated alveoli. Lm: mean linear intercept. In the control (C) group, saline was instilled intratracheally. At day 21, all groups were randomized to receive
saline and bone marrow (BM), adipose (AD), or lung-derived (LD) mesenchymal stem cells (MSC, 1×105 cells) intravenously (IV) or intratracheally (IT).
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well as type II epithelial and endothelial cell damage
(Table 4, Figure 5). In E-SAL animals, the number of par-
enchymal macrophages with the M1 immunophenotype
was increased (Figure 6) with no significant changes in
numbers of macrophages with the M2 immunophenotype.
KC, VEGF, and TGF-β levels in lung tissue were higher in
E-SAL than in C animals (Figure 7). No significant changes
in Est, L were observed between the E-SAL and C groups
(Table 5).
Echocardiography showed increased right ventricle area
and reduced pulmonary artery acceleration time–pulmonary
artery ejection time (PAT/PET) ratio, an indirect index of
pulmonary arterial hypertension (Figure 8), in the E-SAL
group compared to controls.
Delivery of different sources of MSCs
Intravenous route
IV delivery of BM- and AD-MSCs led to a similar reduc-
tion in Lm, fractional area of alveolar collapse, neutrophil
infiltration (Table 3, Figure 2), collagen fiber content
around the small airways (Figure 3), and number of
apoptotic cells (Table 4), and an increase in the amount
of elastic fibers (Figure 4) compared to the E-SAL
group. BM- and AD-MSCs attenuated ultrastructural
damage of the alveolar-capillary membrane, as well asTable 2 Cell characterization by flow cytometry
BM-MSC AD-MSC L-MSC
CD19− 99.29% 99.74% 99.98%
CD29+ 99.00% 99.48% 99.63%
CD34− 96.76% 98.30% 99.62%
CD45− 95.38% 98.40% 88.77%
Sca1+ 58.46% 53.29% 38.76%
BM-MSC: bone marrow-derived mesenchymal stem (stromal) cells; AD-MSC:
adipose tissue-derived mesenchymal stem (stromal) cells; L-MSC: lung tissue-
derived mesenchymal stem (stromal) cells. Flow cytometry reveals that
mesenchymal stem cells are negative (−) for leukocyte (CD45), hematopoietic
(CD34), and B-cells (CD19), while they are concomitantly positive (+) for stem
cell (Sca1) and mesenchymal stem cell markers (CD29).epithelial and endothelial cells (Table 4, Figure 5). BM-
and AD-MSCs reduced the number of macrophages with
the M1 immunophenotype (Figure 6A), but only BM-
MSCs increased the number of macrophages with the M2
immunophenotype in lung parenchyma (Figure 6B). BM-
and AD-MSCs decreased KC and TGF-β levels, but in-
creased VEGF levels in lung tissue (Figure 7). BM- and
AD-MSCs did not modify Est, L (Table 5). BM- and AD-
MSCs led to a significant reversion of the PAT/PET ratio
(Figure 8A) and tended to normalize right ventricle area
(Figure 8B).
Intratracheal route
IT administration of BM-, AD-, and L-MSCs reduced
Lm and neutrophils (Table 3) while increasing elastic
fiber content (Figure 4). AD- and L-MSCs reduced the
fractional area of alveolar collapse, whereas BM-MSCs
decreased the fractional area of lung hyperinflation
(Table 3). Although BM-MSCs, AD-MSCs, and L-MSCs
reduced collagen fiber deposition around the small air-
ways, BM- and L-MSCs were more effective than AD-
MSC (Figure 3). IT administration of all three types of
MSCs attenuated ultrastructural damage of the alveolar-
capillary membrane, as well as type II epithelial and
endothelial cells (Table 4, Figure 5). The number of mac-
rophages with the M2 immunophenotype was higher after
administration of BM-MSCs compared to AD-MSCs
(Figure 6B). All three cell sources reduced TGF-β
levels, but only BM- and L-MSCs significantly de-
creased KC levels (Figure 7). BM-, AD-, and L-MSCs
did not modify Est, L (Table 5). PAT/PET and right ven-
tricle area were not affected by any of the studied MSCs
when administered via the IT route (Figure 8).
Discussion
To our knowledge, this was the first study to compare the
potential therapeutic effects of three different sources of
MSCs, delivered through two different administration
routes, on lung inflammation and remodeling and on car-
diovascular function in experimental emphysema induced
Table 3 Lung morphometry and cellularity
Normal (%) Collapse (%) Hyperinflation (%) Lm (μm) Neutrophils (%)
C 91.25 ± 3.91 8.35 ± 3.61 0.40 ± 1.18 35.92 ± 2.55 1.45 ± 0.93
E
SAL 45.34 ± 10.02* 27.73 ± 13.55* 26.93 ± 12.32* 60.08 ± 6.37* 6.28 ± 0.76*
BM-MSC
IV
55.09 ± 11.99* 15.19 ± 3.17*# 29.73 ± 12.20* 41.45 ± 5.37# 1.80 ± 0.70#
AD-MSC 69.33 ± 10.74*# 9.70 ± 4.48# 21.33 ± 9.01* 38.85 ± 4.25# 1.26 ± 0.76#
BM-MSC
IT
69.03 ± 5.18*# 17.21 ± 4.37* 13.77 ± 5.29*#† 38.39 ± 1.20# 1.39 ± 0.10#
AD-MSC 64.01 ± 14.43*# 13.32 ± 4.12# 22.67 ± 13.10* 35.10 ± 0.82# 0.91 ± 0.12#
L-MSC 66.91 ± 8.53*# 7.79 ± 2.84# 25.31 ± 9.57*‡ 37.27 ± 1.83# 1.46 ± 0.11#
Values expressed as means (±SD) of 7 (E) - 30 (C) animals per group. All values were computed in ten random, non-coincident fields per mice. Fractional area of
normal, collapsed, and hyperinflated alveoli. Lm, mean linear intercept. In the control (C) group, saline was instilled intratracheally. In the emphysema (E) groups,
mice received porcine pancreatic elastase intratracheally. At day 21, all groups were randomized to receive saline and bone marrow (BM), adipose (AD), or lung
(L)-derived mesenchymal stem cells (MSC, 1×105 cells) intravenously (IV) or intratracheally (IT). *Vs. C group (p < 0.05). #Vs. E-SAL group (p < 0.05). †Vs. BM-MSC-IV
group (p < 0.05). ‡Vs. BM-MSC-IT group (p < 0.05).
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single-dose protocols of elastase-induced emphysema
[26], which induce only emphysema-like lesions without
systemic [27] or cardiovascular impairment, the present
model, developed in our laboratory [11], results in lung
histological and ultrastructural changes and cardiac im-
pairment that resemble human emphysema. Using this
model, all studied MSC groups (with the exception of the
IV L-MSC group), regardless of administration route, ex-
hibited decreased Lm, neutrophil infiltration, and cell
apoptosis; increased elastic fiber content; reduced alveolar-
capillary membrane and type II epithelial and endothelial
cell ultrastructural damage; and decreased KC and TGF-β
expression in lung tissue. Therefore, MSC administrationFigure 2 Representative photomicrographs of the lung parenchyma.
(SAL) or bone marrow (BM), adipose (AD), and lung (L)-derived mesenchymcan modulate the inflammatory and remodeling processes
of emphysema; however, specific beneficial effects can dif-
fer depending on MSC source and administration route.
While all MSCs share similar general properties, cells
from different sources can exhibit significant differ-
ences in anti-inflammatory or regenerative potency de-
pending on the particular injury being addressed [28].
Recent studies have compared the characteristics of
adult MSCs from different sources [9,10,17,29], and
have demonstrated distinct effects in different experi-
mental models, even when cells have similar prolifera-
tion and differentiation capacities [30,31]. The relevant
mechanisms whereby different MSCs populations have
distinct actions in the same disease model remainC: control groups. E: emphysema groups. Mice were treated with saline
al stromal cells (MSC). IV: intravenous route. IT: intratracheal route.
Figure 3 Collagen fibers in small airways (Picrosirius-polarization method). C: control groups. E: emphysema groups. Mice were treated
with saline (SAL) or bone marrow (BM), adipose (AD), and lung (L)-derived mesenchymal stromal cells (MSC). IV: intravenous route. IT: intratracheal
route. Values are mean ± SD of 7–30 mice in each group. All values were computed in ten random, non-coincident fields per animal. *Vs. C group
(p < 0.05). #Vs. E-SAL group (p < 0.05).
Table 4 Semiquantitative analysis of electron microscopy and apoptosis (TUNEL)
Alveolar-capillary membrane Endothelial cell lesion Pneumocyte II lesion Apoptosis
C 1 (0–1) 0 (0–1) 1 (0.5–1) 0.5 (0–1)
E
SAL 4 (3–4)* 4 (3–4)* 3 (3–4)* 3.5 (3–4)*
BM–MSC
IV
2 (1.5–2.5)*# 2 (2–2.5)*# 2 (1.5–2.5)*# 1 (1–1.75)#
AD–MSC 2 (1.5–2)*# 2 (1.5–2.5)*# 2 (2–2.5)*# 1.5 (1–2)#
BM–MSC
IT
2 (2–2.5)*# 2 (2–2.5)*# 3 (2–3)*# 1 (1–1.75)#
AD–MSC 2 (1–2)*# 2 (2–3)*# 2 (2–2.5)*# 1 (−1.75)#
L–MSC 2 (2–2.5)*# 3 (2.5–3)*# 2 (2–3)*# 2 (2–2)*#
Values expressed as median (interquartile range) of 4 (E) to 16 (C) animals per group. Pathological findings were graded on a five-point, semiquantitative,
severity-based scoring system: 0 = normal lung parenchyma, 1 = changes in 1–25%, 2 = 26–50%, 3 = 51–75%, and 4 = 76–100% of the examined tissue in control
(C) and emphysema (E) female C57BL/6 mice treated with saline (SAL) or bone marrow (BM), adipose (AD), or lung (L)-derived mesenchymal stem cells (MSC)
intravenously (IV) or intratracheally (IT). *Vs. C group (p < 0.05). #Vs. E-SAL group (p < 0.05).
Antunes et al. Respiratory Research 2014, 15:118 Page 7 of 14
http://respiratory-research.com/content/15/1/118
Figure 4 Elastic fibers in the alveolar septa (Weigert’s resorcin fuchsin method). C: control groups. E: emphysema groups. Mice were
treated with saline (SAL) or bone marrow (BM), adipose (AD), and lung (L)-derived mesenchymal stromal cells (MSC). IV: intravenous route. IT:
intratracheal route. Values are mean ± SD of 7–30 mice in each group. All values were computed in ten random, non-coincident fields per animal.
*Vs. C group (p < 0.05). #Vs. E-SAL group (p < 0.05).
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varied according to source.
BM-MSCs are well-characterized and currently the
most widely used [16]; however, they require an invasive
harvesting process and have limited availability. Like
BM-MSCs [4,7,13], AD-MSCs have also demonstrated
promising effects on the maintenance of vascular integ-
rity by secreting anti-apoptotic and pro-angiogenic
factors [32], and reduce inflammation in experimental
emphysema [6,33]. In adults, these cells are easy to ob-
tain in large quantities by liposuction, which makes
them good candidates for therapeutic use and facilitates
autologous transplantation [34]. More recently, highly
proliferative and clonogenic MSC populations have also
been isolated from explants [35] and allografts [36] of
adult lung tissue. L-MSCs are immunoprivileged, do not
express MHC II or the co-stimulatory molecules CD80
or CD86 [37], and can inhibit T cell-based allorecognition
[36], facilitating the success of allogeneic transplants. Add-
itionally, L-MSCs express several basement membrane
proteins and growth factors which seem to amplify their
retention in the injured tissue [12,14], making thempromising candidates for cell-based therapy in lung dis-
eases. However, there is limited information regarding the
effects of L-MSCs in experimental emphysema [12,14,35].
In contrast to the present study, Hoffman et al. (13) ob-
served no death after IV delivery of L-MSCs in mice. The
reasons for this discrepancy are unclear; one potential ex-
planation is the route (jugular versus tail vein) chosen for
cell administration. Since no significant differences be-
tween saline and lung fibroblasts were observed in our
pilot studies, nor in previous reports [38,39], saline was
administered as control instead of mouse fibroblasts in
the present investigation.
Reports have demonstrated that a direct pathway of de-
livery – e.g., IT for lung diseases [24] and intra-myocardial
for acute ischemia-reperfusion [40] – may result in greater
retention of MSCs in the target tissues. However, in an ex-
perimental model of ventilator-induced lung injury, MSCs
enhanced recovery and repair regardless of administration
route (IT vs. IV) [38]. Recent evidence demonstrated that
neither IV nor IT administration of BM-MSC is able to re-
vert lung histology in a single dose protocol of elastase-
induced emphysema [41], while in the present study, IT
Figure 5 Electron microscopy of lung parenchyma. C: control groups. E: emphysema groups. Mice were treated with saline (SAL), or bone
marrow (BM), adipose (AD) and lung (L)-derived mesenchymal stem cells (MSC). In the C group, the alveolar epithelium is formed by type II
pneumocytes (PII). Alveolar septa (AS) and capillaries (CAP) are intact. In E-SAL group, the AS is ruptured with capillary loss (arrows) and shows
fibroblasts (FIB) and increase in collagen fibers. The alveolar epithelium was apparently normal but had zones with AS thickness containing no
capillaries (arrows) even after intravenous or intratracheal BM-MSC and AD-MSC administration. After intratracheal L-MSC treatment, the AS is
restored with new capillaries and collagen fibers are diminished.
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alveolar hyperinflation than IV delivery. This dissociation
between the beneficial effects observed in the present
study with IT administration versus those obtained with
IV administration may be associated with great loss of al-
veolar membrane surface area in emphysema, resulting in
reduced endothelial cell adhesion molecules [42] and,
thus, decreased MSC adhesion.
In our emphysema model, the increase in Lm was asso-
ciated with neutrophil infiltration of lung tissue and M1
macrophage polarization. Conflicting evidence on the ef-
fects of smoking in downregulating M1 macrophages hasbeen published [43-46]. Macrophages can be activated by
various extracellular signals to polarize toward either the
M1 (inflammatory and antimicrobial) or the M2 (wound
repair and inflammation resolution) phenotype. The en-
hanced M1 polarization observed in lung tissue in our
experiment is in line with some reports, which evinced
an increase in pro-inflammatory macrophages and a re-
duction of chemokine ligand 18 (CCL18), a chemokine
expressed by alternatively activated macrophages, in the
bronchoalveolar lavage fluid of smokers compared to
nonsmokers [43,44]. In the present study, M1 activation
was similarly inhibited by IV delivery of BM-MSC and
Figure 6 Immunohistochemistry for iNOS (A) and arginase-1 (B). C: control groups. E: emphysema groups. Mice were treated with saline
(SAL), or bone marrow (BM), adipose (AD) and lung (L)-derived mesenchymal stem cells (MSC). IV: intravenous route. IT: intratracheal route. Values
are mean ± SD of 5–30 mice in each group. All values were computed in ten random, non-coincident fields per animal. *Vs. C group (p < 0.05).
#Vs. E-SAL group (p < 0.05). Note positive cells in brown (arrow).
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the M2 phenotype, and more effectively when given IV
than when administered IT. The differences in M1 and
M2 phenotype observed according to the MSC source
and route of administration may be explained by the
existence of an “environmental-niche memory” in BM-Figure 7 Levels of KC (A), VEGF (B), and TGF-β (C) in lung tissue. C: co
(SAL), or bone marrow (BM), adipose (AD) and lung (L)-derived mesenchym
are mean ± SD of 5–30 mice in each group. All values were computed in t
#Vs. E-SAL group (p < 0.05).MSCs and an “epithelial” commitment of AD-MSCs, as
described in a previous report [29].
In the present study, BM-, AD-, and L-MSCs seemed
to differentially modulate production of some chemo-
kines and growth factors associated with the pathophysi-
ology of emphysema. Increasing evidence demonstratesntrol groups. E: emphysema groups. Mice were treated with saline
al stem cells (MSC). IV: intravenous route. IT: intratracheal route. Values
en random, non-coincident fields per animal. *Vs. C group (p < 0.05).
Table 5 Lung mechanics
Groups Est (cmH2O.ml
−1)
C 30.26 ± 2.27
E








AD-MSC 35.66 ± 5.39
L-MSC 29.62 ± 4.00
Static lung elastance (Est, L) at day 28. In the control (C) group, saline was instilled
intratracheally once a week for 1 month. Emphysema (E) animals received porcine
pancreatic elastase intratracheally following the same protocol. After the last
instillation, all groups were randomized to receive saline (SAL) and mesenchymal
stem cells (MSC, 1×105 cells) derived from bone marrow (BM), adipose tissue (AD),
or lung tissue (LD) intravenously (IV) or intratracheally (IT). Values are means ± SD
of 7 (E) – 30 (C) animals in each group (10 determinations per animal).
Figure 8 Short-axis B-dimensional views of both ventricles. The indice
ejection time ratio – PAT/PET ratio – and (B) right ventricle area. (C) Echocard
the means of 3 mice ± SD/group. C: control groups. E: emphysema groups. M
and lung (L)-derived mesenchymal stem cells (MSC). IV: intravenous route. IT:
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http://respiratory-research.com/content/15/1/118that the pathogenic changes mediated by MSCs are
highly sensitive to the microenvironment to which these
cells are exposed. For example, MSC-conditioned media
may be a rich source of TGF-β secretion and lead to an
increase in collagen gene expression [47]. Conversely, in
an experimental model of bleomycin-induced fibrosis,
BM-MSCs reduced lung tissue TGF-β levels and soluble
collagen in lung extracts [48]. In emphysema, increased
TGF-β secretion by epithelial cells [49] is associated with
progressive small-airway fibrosis. In our study, a similar
reduction of TGF-β levels was observed in all MSC-
treated groups, regardless of the delivery route; however,
it was not accompanied by equal decrease in deposition
of collagen fibers in the small airways. Previous reports
demonstrated the ability of MSCs to stimulate VEGFs shown are (A) pulmonary artery acceleration time/pulmonary artery
iographic images. LV: left ventricle, RV: right ventricle. The bars represent
ice were treated with saline (SAL), or bone marrow (BM), adipose (AD)
intratracheal route. *Vs. C group (p < 0.05). #Vs. E-SAL group (p < 0.05).
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mental models of emphysema. We observed that IV ad-
ministration of BM-MSC and AD-MSC increased
VEGF levels in lung tissue, which was not observed
with the IT route. Based on previous studies of cardiac
revascularization [50,51], we hypothesize that the sys-
temic injection of BM-MSCs and AD-MSCs results in
direct contact with the remaining endothelial cells of the
pulmonary vasculature, stimulating them to synthesize
VEGF. Intense neutrophilia in the sputum of COPD pa-
tients correlates positively with disease severity and
high production of IL-8 [52]. This chemokine is re-
leased by alveolar macrophages when stimulated by
pollutant particles, and is responsible for massive neu-
trophil recruitment to the lungs. We observed that all
MSC therapies similarly reduced KC and neutrophilia
in lung tissue.
Only IV administration of BM-MSC and AD-MSC
reverted the reduction in the PAT/PET ratio, which may
be associated with the inhibition of pulmonary micro-
vasculature muscularization and stimulation of VEGF-
induced angiogenesis [4]. Nevertheless, these changes
did not result in modifications in right ventricular area,
probably due to the timing of analysis and the small
number of cells that reach the heart.
Despite the major lung morphology changes induced
by our model of emphysema, no significant changes in
Est, L were observed. This is in agreement with other
studies using different experimental models of emphy-
sema, which showed dissociation between the degree of
tissue loss and pulmonary dysfunction [53-55].
Several limitations of this study should be considered:
(1) the absence of MSC tracking after IT or IV adminis-
tration, limiting our knowledge regarding the delivery
dynamics of each cell lineage; (2) the experimental
period of 5 weeks, which may not be enough to under-
stand the late effects of MSC therapy; and (3) only a few
specific cytokines and growth factors were evaluated; a
wider range of mediators should be analyzed to provide
a more complete understanding of the mechanisms as-
sociated with each cell type. Additionally, more extensive
analysis of the range of soluble mediators released by
each MSC type may provide further information on the
different effects noted in this model.
In conclusion, all three MSC sources tested (BM-
MSC, AD-MSC and L-MSC), regardless of the adminis-
tration route (with the exception of the IV L-MSC
group), attenuated lung damage in this mouse model of
elastase-induced experimental emphysema. Nevertheless,
MSCs from different sources exhibited distinct effects
on the different aspects of lung and cardiovascular in-
jury, through mechanisms that remain unclear. Further
research comparing the effects of different MSC sources
and routes of administration is required.Competing interest
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